Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer.

Abstract

BACKGROUND:

In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs.

PATIENTS AND METHODS:

Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated.

RESULTS:

Using the modified methodology, CTCs were detectable in 49% of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year.

CONCLUSION:

Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.

• Authors: Sumanta K Pal, Miaoling He, Timothy Wilson, Xueli Liu, Keqiang Zhang, Courtney Carmichael, Alejandra Torres, Sonya Hernandez, Clayton Lau, Neeraj Agarwal, Mark Kawachi, Yun Yen, Jeremy O Jones
• Journal: Clinical genitourinary cancer (Clin Genitourin Cancer) Vol. 13 Issue 2 Pg. 130-6 (Apr 2015) ISSN: 1938-0682 [Electronic] United States
• PMID: 25450039 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• AC133 Antigen
• Antigens, CD
• Biomarkers, Tumor
• Cadherins
• Glycoproteins
• PROM1 protein, human
• Peptides

Topics

• AC133 Antigen
• Aged
• Antigens, CD (metabolism)
• Biomarkers, Tumor (metabolism)
• Cadherins (metabolism)
• Cell Count
• Cell Separation (methods)
• Epithelial-Mesenchymal Transition
• Feasibility Studies
• Glycoproteins (metabolism)
• Humans
• Male
• Middle Aged
• Neoplastic Cells, Circulating (metabolism, pathology)
• Peptides (metabolism)
• Phenotype
• Prognosis
• Prospective Studies
• Prostatic Neoplasms (blood, pathology)